Rebecca Kruse-Jarres

List of Publications by Year
in descending order

25	1,822	840776 11	752698 20
papers	citations	h-index	g-index

26	26	26	1297
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine, 2017, 377, 809-818.	27.0	794
2	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. New England Journal of Medicine, 2018, 379, 811-822.	27.0	489
3	Acquired hemophilia <scp>A</scp>: Updated review of evidence and treatment guidance. American Journal of Hematology, 2017, 92, 695-705.	4.1	267
4	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
5	How I treat type 2B von Willebrand disease. Blood, 2018, 131, 1292-1300.	1.4	40
6	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective nonâ€interventional study in a realâ€world setting. Haemophilia, 2019, 25, 213-220.	2.1	31
7	Healthâ€related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, nonâ€interventional study (NIS). Haemophilia, 2019, 25, 382-391.	2.1	28
8	Identification and Basic Management of Bleeding Disorders in Adults. Journal of the American Board of Family Medicine, 2014, 27, 549-564.	1.5	20
9	Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multiâ€centre, nonâ€interventional study. Haemophilia, 2018, 24, 921-929.	2.1	20
10	Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A. Hematology American Society of Hematology Education Program, 2011, 2011, 407-412.	2.5	18
11	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis, 2021, 19, 32-41.	3.8	14
12	Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatric Blood and Cancer, 2020, 67, e28474.	1.5	11
13	Serum 25-Hydroxyvitamin D and Diet Mediates Vaso-Occlusive Related Hospitalizations in Sickle-Cell Disease Patients. Nutrients, 2018, 10, 1384.	4.1	7
14	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis, 2021, 19, 21-31.	3.8	7
15	Emicizumab in Hemophilia A. New England Journal of Medicine, 2020, 382, 785-786.	27.0	4
16	Reduced production of IFN-Î³ and LT-Î± is associated with successful prednisone therapy in patients with acquired hemophilia A: A pilot study. Thrombosis Research, 2011, 128, e86-e90.	1.7	3
17	Phase II Trial of Rituximab in the Treatment of Inhibitors in Congenital Hemophilia A: Results of the RICH Study. Blood, 2011, 118, 27-27.	1.4	2
18	Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction. Blood, 2013, 122, 1106-1106.	1.4	2

#	Article	IF	Citations
19	Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial. Blood, 2013, 122, 206-206.	1.4	1
20	Baseline Characteristics Associated with Vitamin D Deficiency in Sickle Cell Disease and the Effect of Vitamin D Replacement. Blood, 2011, 118, 2139-2139.	1.4	1
21	Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment. Haemophilia, 2021, 27, e479-e483.	2.1	0
22	Vitamin D Deficiency In Pediatric Patients with Sickle Cell Disease Correlates with Reticulocytosis but Not with Clinical Disease Severity. Blood, 2010, 116, 4820-4820.	1.4	0
23	Immune Tolerance Induction (ITI) in Adults with Congenital Hemophilia: A Multicenter Experience. Blood, 2012, 120, 1123-1123.	1.4	0
24	Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results.. Blood, 2012, 120, 2224-2224.	1.4	0
25	Analysis Of Hemostatic CharacteristicsÂusing ThromboelastometryÂinÂAdults With Sickle Cell DiseaseÂand Controls. Blood, 2013, 122, 4766-4766.	1.4	0